MX2019013626A - Modo de accion dual novedoso de activadores de guanilato ciclasa solubles e inhibidores de fosfodiesterasa y usos de los mismos. - Google Patents

Modo de accion dual novedoso de activadores de guanilato ciclasa solubles e inhibidores de fosfodiesterasa y usos de los mismos.

Info

Publication number
MX2019013626A
MX2019013626A MX2019013626A MX2019013626A MX2019013626A MX 2019013626 A MX2019013626 A MX 2019013626A MX 2019013626 A MX2019013626 A MX 2019013626A MX 2019013626 A MX2019013626 A MX 2019013626A MX 2019013626 A MX2019013626 A MX 2019013626A
Authority
MX
Mexico
Prior art keywords
dual mode
guanylate cyclase
phosphodiesterase inhibitors
soluble guanylate
novel dual
Prior art date
Application number
MX2019013626A
Other languages
English (en)
Inventor
Naef Reto
Tenor Hermann
Original Assignee
Topadur Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topadur Pharma Ag filed Critical Topadur Pharma Ag
Publication of MX2019013626A publication Critical patent/MX2019013626A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La presente invención se refiere a compuestos de fórmula I,(ver formula I) o sal, solvato o hidrato de los mismos farmacéuticamente aceptables, y su uso en métodos para tratar o prevenir una enfermedad aliviada por la inhibición de PDE5 en un humano o en un mamífero no humano.
MX2019013626A 2017-05-22 2018-05-22 Modo de accion dual novedoso de activadores de guanilato ciclasa solubles e inhibidores de fosfodiesterasa y usos de los mismos. MX2019013626A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17172193 2017-05-22
PCT/EP2018/063339 WO2018215433A1 (en) 2017-05-22 2018-05-22 Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2019013626A true MX2019013626A (es) 2020-01-13

Family

ID=58772403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013626A MX2019013626A (es) 2017-05-22 2018-05-22 Modo de accion dual novedoso de activadores de guanilato ciclasa solubles e inhibidores de fosfodiesterasa y usos de los mismos.

Country Status (14)

Country Link
US (2) US11155558B2 (es)
EP (1) EP3630769A1 (es)
JP (1) JP7182568B2 (es)
KR (1) KR20200010228A (es)
CN (1) CN110621676B (es)
AU (1) AU2018274599B9 (es)
BR (1) BR112019024300A2 (es)
CA (1) CA3060525A1 (es)
IL (1) IL269835B (es)
MX (1) MX2019013626A (es)
PH (1) PH12019550217A1 (es)
RU (1) RU2758373C2 (es)
WO (1) WO2018215433A1 (es)
ZA (1) ZA201908389B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3887376A1 (en) * 2018-11-28 2021-10-06 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CA3166602A1 (en) 2020-02-05 2021-08-12 Nicoletta Almirante Compositions for the treatment of glaucoma and ocular hypertension
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR20220009806A (ko) * 2020-07-16 2022-01-25 제이투에이치바이오텍 (주) 이중 억제제 화합물 및 이들의 의약 용도
EP4236952A1 (en) 2020-11-02 2023-09-06 Nicox S.A. No-pde5 inhibitor for use in treating dry age-related macular degeneration, geographic atrophy and glaucoma-associated neurodegeneration
WO2023166013A1 (en) 2022-03-02 2023-09-07 Topadur Pharma Ag Topical compositions and uses therof
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB2346877B (en) 1997-11-12 2001-12-05 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
CA2312900A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
WO2001096334A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US6831074B2 (en) * 2001-03-16 2004-12-14 Pfizer Inc Pharmaceutically active compounds
FR2842809A1 (fr) 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
US20020182162A1 (en) 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
CN100374441C (zh) * 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
WO2005026145A2 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
CN1966506A (zh) 2005-11-17 2007-05-23 上海特化医药科技有限公司 吡唑并嘧啶酮衍生物及其制备方法和用途
AU2006341342B2 (en) 2006-04-04 2010-05-20 Dong-A Pharmaceutical.Co., Ltd. Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound
BRPI1006869A2 (pt) 2009-01-17 2016-03-15 Bayer Schering Pharma Ag estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP2512479B1 (en) 2009-12-18 2016-03-30 Exodos Life Sciences Limited Partnership Compositions for treating peripheral vascular disease
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物

Also Published As

Publication number Publication date
RU2758373C2 (ru) 2021-10-28
PH12019550217A1 (en) 2020-09-14
RU2019133200A3 (es) 2021-06-23
JP7182568B2 (ja) 2022-12-02
ZA201908389B (en) 2020-11-25
US11155558B2 (en) 2021-10-26
CA3060525A1 (en) 2018-11-29
WO2018215433A1 (en) 2018-11-29
AU2018274599B9 (en) 2022-04-07
EP3630769A1 (en) 2020-04-08
BR112019024300A2 (pt) 2020-06-16
IL269835B (en) 2022-08-01
US11905293B2 (en) 2024-02-20
RU2019133200A (ru) 2021-06-23
JP2020520945A (ja) 2020-07-16
US20200181149A1 (en) 2020-06-11
AU2018274599A1 (en) 2019-11-14
CN110621676A (zh) 2019-12-27
KR20200010228A (ko) 2020-01-30
US20220073529A1 (en) 2022-03-10
IL269835A (en) 2019-11-28
AU2018274599B2 (en) 2022-03-03
CN110621676B (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
PH12019550217A1 (en) Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
SA519401541B1 (ar) [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات
MX2019004204A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
PH12019500480A1 (en) Pyridine compound
SA518400660B1 (ar) مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2
PH12016500359A1 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
MX2017013797A (es) Inhibidor de janus quinasa.
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
EA201500930A1 (ru) Новые ингибиторы
WO2015171526A3 (en) Tricyclic pyrazolopyridine compounds
MX2018004664A (es) Antagonistas de ep4.
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
MX2019004626A (es) Compuesto de piridona como inhibidor de c-met.
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
PH12015501643A1 (en) Methods of use of phenoxypropylamine compounds to treat depression
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.
BR112018009805A2 (pt) derivados 2-fenil-3,4-di-hidropirrolo [2,1-f][1,2,4]triazinona como inibidores de fosfodiesterase e usos dos mesmos